Abstract
Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) are parenteral anticoagulants commonly used to prevent and treat thromboembolism. These agents are included on the Institute for Safe Medication Practices (ISMP) list of medications that have an increased risk of causing severe patient injury when used in error. Thus the management plan for patients receiving UFH and LMWHs should be thorough and individualized. When constructing an individualized care plan, several factors should be addressed to optimize therapy with UFH and LMWH including the utilization of dosing algorithms for initial and maintenance doses, monitoring laboratory results and adjusting therapy appropriately, providing patient education, and addressing barriers to outpatient use if needed (self-administration techniques, financial burdens, etc). Pharmacists are in the ideal position to address all of these expectations. This chapter outlines the role of the pharmacist in the management of patients on UFH and LMWH.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Heparin sodium injection [package insert] (2014) Hospira Inc, Lake Forest
Enoxaparin sodium injection [package insert] (2013) Amphastar Pharmaceuticals Inc, Rancho Cucamonga
Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568
Bond CA, Raehl CL (2008) 2006 national clinical pharmacy services survey: clinical pharmacy services, collaborative drug management, medication errors, and pharmacy technology. Pharmacotherapy 28:1–13
Phillips KW, Wittkowsky AK (2007) Survey of pharmacist-managed inpatient anticoagulation services. Am J Health Syst Pharm 64:2275–2278
Chenella FC, Klotz TA, Gill MA et al (1983) Comparison of physician and pharmacist management of anticoagulant therapy of inpatients. Am J Hosp Pharm 40:1642–1645
Pawloski SJ, Kersh PL (1992) Therapeutic heparin monitoring service in a small community hospital. Hosp Pharm 27:703–706
Kershaw B, White RH, Mungall D et al (1994) Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service. Arch Intern Med 154:1005–1011
Saya FG, Coleman LT, Martinoff JT (1985) Pharmacist-directed heparin therapy using a standard dosing and monitoring protocol. Am J Hosp Pharm 42:1965–1969
Rivey MP, Peterson JP (1993) Pharmacy-managed, weight-based heparin protocol. Am J Hosp Pharm 50:279–284
Bond CA, Raehl CL (2004) Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, medicare charges, bleeding complications, and transfusions. Pharmacotherapy 24:953–963
Price CK, Colodny L (2000) Partnering with nurses to manage heparin therapy with a weight-based protocol. Am J Health Syst Pharm 57(110–112):115–116
Bauer JB, Chun DS, Karpinski TA (2008) Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm 65:1643–1647
Maynard G, Humber D, Jenkins I (2014) Multidisciplinary initiative to improve inpatient anticoagulation and management of venous thromboembolism. Am J Health System Pharm 71:305–310
Bridges GC, Lee MD, Jenkins JK et al (2003) Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: The LEAP program. J Trauma 54:232–235
Brown G, Dodek P (1997) An evaluation of empiric vs. nomogram based dosing of heparin in an intensive care unit. Crit Care Med 25:1534–1538
Raschke RA, Reilly BM, Guidry JR et al (1993) The weight based heparin dosing nomogram compared with the standard of care nomogram. Ann Intern Med 119:874–881
Gunnarsson PS, Sawyer WT, Montague D et al (1995) Appropriate use of heparin: empiric vs nomogram-based dosing. Arch Intern Med 155:526–532
Shalansky KF, FitzGerald M, Sunderji R et al (1996) Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 16:1076–1084
Tsang D, Shalansky KF, Lum E (2009) Evaluation of 2 weight-based protocols for administration of heparin. Can J Hosp Pharm 62:448–456
Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest Physicians (2012) Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e24s–e43s
Dalteparin. [package insert] (2014) Pfizer, Kirkland
Tinzaparin [package insert] (2010) LEO Pharmaceuticals Company, Parsipany
Nadroparin [package insert] (2011) GlaxoSmithKline Inc, Mississauga
Rajgopal R, Bear M, Butcher M et al (2008) The effects of heparin and low molecular weight heparins on bone. Thromb Res 122:293–298
Vandiver JW, Vondracek TG (2012) Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 32:546–558
Favaloro EJ, Bonar R, Sioufi J et al (2005) An international survey of current practice in the laboratory assessment of anticoagulation therapy with heparin. Pathology 37:234–238
Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS (2011) Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45:861–868
Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e152S–e184S
Michelson AD, Bovill E, Monagle P et al (1998) Antithrombotic therapy in children. Chest 114:748–769
Dobesh PP, Trujillo TC, Finks SW (2013) Role of the pharmacist in achieving performance measures to improve the prevention and treatment of venous thromboembolism. Pharmacotherapy 33:650–664
The Joint Commission. Hospital Accreditation Program: National patient safety goals effective 1 Jan 2015. Available at: http://www.jointcommission.org/assets/1/6/2015_NPSG_HAP.pdf. Accessed 20 Feb 2015
Zed PJ, Filiatrault L (2008) Clinical outcomes and patient satisfaction of a pharmacist-managed, emergency department-based outpatient treatment program for venous thromboembolic disease. CJEM 10:10–17
Al-Dorzi HM, Cherfan A, Al-Harbi S et al (2013) Knowledge of thromboprophylaxis guidelines pre- and post-didactic lectures during a venous thromboembolism awareness day at a tertiary-care hospital. Ann Thorac Med 8:165–169
Dobesh PP, Stacy ZA (2005) Effect of a clinical pharmacy education program on improvement in the quantity and quality of venous thromboembolism prophylaxis for medically ill patients. J Manag Care Pharm 11:755–762
Institute for Safe Medication Practices. ISMP’s List of High-Alert Medications. www.ismp.org/tools/highalertmedications.pdf. Accessed: 20 Feb 2015
Khoo AL, Teng M, Lim BP, Tai HY, Lau TC (2013) A multicenter, multidisciplinary, high-alert medication collaborative to improve patient safety: the Singapore experience. Jt Comm J Qual Patient Saf 39:205–212
Harder KA, Bloomfield JR, Sendelbach SE et al (2005) Improving the safety of heparin administration by implementing a human factors process analysis. In: Advances in Patient Safety: From Research to Implementation (Agency for Healthcare Research and Quality Publication No. 05–0021, vol. 3). Rockville (MD): Agency for Healthcare Research and Quality
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Stromich, A. (2015). Unfractionated Heparin and Low Molecular Weight Heparin. In: Rose, A. (eds) Anticoagulation Management. Adis, Cham. https://doi.org/10.1007/978-3-319-22602-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-22602-6_3
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-22601-9
Online ISBN: 978-3-319-22602-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)